Fortress Biotech, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Fortress Biotech, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q4 2024.
  • Fortress Biotech, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $16.2M, a 337% increase year-over-year.
  • Fortress Biotech, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $32.6M, a 91.6% increase year-over-year.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $32.6M, a 91.6% increase from 2023.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17M, a 25.9% decline from 2022.
  • Fortress Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $23M, a 18% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $32.6M $16.2M +$12.5M +337% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 $20.1M $6.57M +$2.2M +50.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $17.9M $5M +$781K +18.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $17.2M $4.86M +$126K +2.66% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $17M $3.7M -$1.8M -32.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 $18.8M $4.38M -$2.46M -36% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $21.3M $4.22M -$864K -17% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $22.2M $4.73M -$832K -15% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $23M $5.51M -$1.53M -21.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $24.5M $6.84M +$2.51M +58% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $22M $5.08M +$731K +16.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $21.3M $5.56M +$1.79M +47.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $19.5M $7.04M +$3.91M +125% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $15.6M $4.33M +$1.16M +36.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $14.4M $4.35M +$602K +16.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $13.8M $3.77M +$373K +11% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $13.5M $3.13M +$367K +13.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $13.1M $3.17M -$570K -15.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $13.7M $3.75M +$375K +11.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $13.3M $3.4M +$91K +2.75% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $13.2M $2.77M Oct 1, 2019 Dec 31, 2019 10-K/A 2021-04-09
Q3 2019 $3.74M -$365K -8.89% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $3.37M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $3.31M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q3 2018 $4.11M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q1 2016 $1.1M -$1.9M -63.3% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-10
Q1 2015 $3M Jan 1, 2015 Mar 31, 2015 10-K 2016-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.